US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

11.42

-0.1900-1.64%

Post-market: 11.420.00000.00%19:57 EDT

Volume:407.86K

Turnover:4.67M

Market Cap:631.01M

PE:9.68

High:11.61

Open:11.61

Low:11.42

Close:11.61

52wk High:13.59

52wk Low:11.42

Shares:55.25M

Float Shares:55.25M

Volume Ratio:1.27

T/O Rate:0.74%

Dividend:1.42

Dividend Rate:12.40%

EPS(TTM):1.18

ROE:--

ROA:--

PB:0.79

PE(LYR):- -

Loading ...

Overview Company News Filings

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Brookfield Real Assets Income Fund Inc. Declares Q4 2026 Distribution Schedule

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

C4X Discovery establishes in vivo proof of concept for its PAD4 inhibitor programme

Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Spyre Therapeutics announces results from RA sub-study of SKYWAY basket trial

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Heron Therapeutics Announces Second Quarter 2026 Financial Results

Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Federal Jury Rules Avilar and RA Capital Guilty of Willfully Misusing Yale University's Trade Secrets

Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management

MT Newswires Live

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/RA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":11.42,"timestamp":1791230400000,"preClose":11.61,"halted":0,"volume":407856,"hourTrading":{"tag":"盘后","latestPrice":11.42,"preClose":11.42,"latestTime":"19:57 EDT","volume":208,"amount":2375.58,"timestamp":1791244662180,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.016365202411714,"floatShares":55245934,"shares":55254696,"eps":1.18,"marketStatus":"Closed","change":-0.19,"latestTime":"10-05 16:00:00 EDT","open":11.61,"high":11.61,"low":11.415,"amount":4668357.298752,"amplitude":0.016796,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.18,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791273600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":11.61,"dividendRate":0.124037,"preHourTrading":{"tag":"盘前","latestPrice":11.67,"preClose":11.61,"latestTime":"08:43 EDT","volume":26,"amount":303.42,"timestamp":1791204191510,"change":0.06,"changeRate":0.005168,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.42,"preClose":11.42,"latestTime":"19:57 EDT","volume":208,"amount":2375.58,"timestamp":1791244662180,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.266624},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.266624,"shares":55254696,"dividePrice":1.4165,"high":11.61,"amplitude":0.016796,"preClose":11.61,"low":11.415,"week52Low":11.415,"pbRate":"0.79","week52High":13.59,"institutionHeld":0,"latestPrice":11.42,"eps":1.18,"divideRate":0.124037,"volume":407856,"delay":0,"ttmEps":1.18,"open":11.61,"prevYearClose":12.96,"prevWeekClose":11.61,"prevMonthClose":11.55,"prevQuarterClose":11.55,"fiveDayClose":11.54,"twentyDayClose":12.51,"sixtyDayClose":12.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-12-10","symbol":"RA","amount":0.118,"announcedDate":"2026-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-12-10","defaultRemindTime":1796913000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-12-24","payableDate":"2026-12-10","currency":"USD","dateTimestamp":1796878800000,"payDate":"2026-12-24"},{"date":"2026-11-12","symbol":"RA","amount":0.118,"announcedDate":"2026-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-11-12","defaultRemindTime":1794493800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-11-27","payableDate":"2026-11-12","currency":"USD","dateTimestamp":1794459600000,"payDate":"2026-11-27"},{"date":"2026-10-09","symbol":"RA","amount":0.118,"announcedDate":"2026-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-10-09","defaultRemindTime":1791552600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-23","payableDate":"2026-10-09","currency":"USD","dateTimestamp":1791518400000,"payDate":"2026-10-23"},{"date":"2026-09-10","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-10","defaultRemindTime":1789047000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-24","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1789012800000,"payDate":"2026-09-24"},{"date":"2026-08-06","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-06","defaultRemindTime":1786023000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-20","payableDate":"2026-08-06","currency":"USD","dateTimestamp":1785988800000,"payDate":"2026-08-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671220149","title":"Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220149","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220149?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":"New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indicationsSUNNYVALE, Calif., Sept.  30, 2026 (GLOBE NEWSWI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371750/0/en/ceribell-receives-fda-510-k-clearance-for-quantitative-eeg-trending-and-amplitude-integrated-eeg-analysis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","SAH","BK4588","AMPL","CBLL","LABU","BK4082","BK4585","RA","BK4214"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670889427","title":"Brookfield Real Assets Income Fund Inc. Declares Q4 2026 Distribution Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2670889427","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670889427?lang=en_us&edition=fundamental","pubTime":"2026-09-26 05:04","pubTimestamp":1790370240,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  25, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund’s monthly dist","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/25/3369341/0/en/brookfield-real-assets-income-fund-inc-declares-q4-2026-distribution-schedule.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669462171","title":"Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2669462171","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669462171?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":"Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjgren’s disease in December CLN-049 (FLT3 TCE) upda","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368185/0/en/cullinan-therapeutics-highlights-fourth-quarter-2026-milestones-across-immunology-and-oncology-t-cell-engager-portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","BK4139","RA","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617779","title":"C4X Discovery establishes in vivo proof of concept for its PAD4 inhibitor programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617779","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617779?lang=en_us&edition=fundamental","pubTime":"2026-09-15 15:00","pubTimestamp":1789455600,"startTime":"0","endTime":"0","summary":"A potent and selective PAD4 inhibitor demonstrates efficacy comparable to an anti-TNFα biologic in a mouse model of arthritis 15 September 2026– C4X Discovery Holdings Ltd (\"C4XD\"), a pioneering Drug ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/15/3361668/0/en/c4x-discovery-establishes-in-vivo-proof-of-concept-for-its-pad4-inhibitor-programme.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4162","CIA","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378124","title":"Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378124","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378124?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:30","pubTimestamp":1788867000,"startTime":"0","endTime":"0","summary":"Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357530/0/en/artiva-biotherapeutics-provides-update-on-planned-allonk-data-disclosures-and-development-milestones-for-the-remainder-of-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322782","title":"Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322782","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322782?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865200,"startTime":"0","endTime":"0","summary":"Topline results from UPSTREAM MG’s 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacice","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357492/0/en/vor-completes-enrollment-of-global-phase-3-upstream-mg-trial-and-expands-telitacicept-global-franchise-into-ocular-myasthenia-gravis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4123","SLE","IE0031619046.USD","MG","RA","BK4077","IE00B66KJ199.SGD","IE00B19Z4B17.USD","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811265","title":"Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811265","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811265?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:30","pubTimestamp":1788352200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355154/0/en/artiva-biotherapeutics-to-participate-in-upcoming-investor-conferences-in-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662008070","title":"Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008070","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662008070?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:28","pubTimestamp":1787858880,"startTime":"0","endTime":"0","summary":"LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune diseaseLISRAYA is a once-daily pill that directly targets ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/27/3352364/34323/en/priovant-announces-fda-approval-of-lisraya-brepocitinib-for-adults-with-dermatomyositis-now-available-in-the-u-s.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4588","RA","BK4157","BK4585","MACE","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754700","title":"Spyre Therapeutics announces results from RA sub-study of SKYWAY basket trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662754700?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:05","pubTimestamp":1787688312,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Both ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-results-from-ra-sub-study-of-skyway-basket-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-results-from-ra-sub-study-of-skyway-basket-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","SYRE","BK4139","BK4007","RA","LFSC","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175441","title":"Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175441?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":"Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350866/0/en/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-arthritis-sub-study-of-the-skyway-phase-2-trial-of-spy072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4139","BK4007","SYRE","BK4539","LFSC","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660178421","title":"Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660178421","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660178421?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:26","pubTimestamp":1787142360,"startTime":"0","endTime":"0","summary":"Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected byyear-end RA is a $24 billion m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347616/0/en/chemomab-therapeutics-announces-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSC","IBD","BK4539","MTRS","BK4007","RA","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659009089","title":"Press Release: First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659009089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659009089?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:15","pubTimestamp":1786565700,"startTime":"0","endTime":"0","summary":"-- Completed enrollment for Cohort 1  of Phase 1b ANB033. trial in celiac disease ; top-line Cohort 1 data reaffirmed for Q4. -- Cohort 2  enhanced to enroll up to 40 patients including. those with a broad range of histologic  and symptom. severity to further inform future development; top-line Cohort 2 data. -- U.S. FDA granted Fast Track designation for ANB033 for the treatment of. -- Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis. -- Reiterating cash-runway into Q2 2028, including the expansion of ANB033. -- U.S. FDA granted Fast Track designation to ANB033 for the. treatment of people with CeD on a gluten-free diet. -- 70-patient trial assessing one dose level of subcutaneously. -- Cohort 1  is a gluten-challenge study to assess the. -- Cohort 2  assesses the possibility of mucosal healing","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLE","RA","TRAX","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658915593","title":"Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658915593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658915593?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:30","pubTimestamp":1786455000,"startTime":"0","endTime":"0","summary":"placebo-controlled Phase 3 registrational trial with an open-label. extension assessing the efficacy and safety of telitacicept in gMG. -- Topline data anticipated in 1H 2027Primary Sjgren's Disease-- UPSTREAM SjD. efficacy and safety of telitacicept in SjDCorporate Updates-- Appointed David Zaccardelli, Pharm.D., former Chief Executive Officer and. President of Verona Pharma, to its Board of Directors. approved telitacicept for the treatment of adult patients with SjD and. -- Results from the Phase 3 TELIGAN trial evaluating telitacicept in IgAN in. China were published in The New England Journal of MedicineSecond Quarter 2026 Financial Results-- Cash Position: Cash, cash equivalents and marketable securities were. $466.1 million as of June 30, 2026, which together with the $48.4 million. net proceeds from at-the-market sales during July 2026, are projected to. -- Research & Development (R&D) Expenses: R&D expenses for the second. quarter of 2026 were $25.9 million, compared to $261.5","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4139","VOR","SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658693652","title":"Heron Therapeutics Announces Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658693652","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658693652?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF net revenue grew 35% and APONVIE net revenue grew 74% year-over-year – Amended credit facility with Hercules Capi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341780/0/en/heron-therapeutics-announces-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","HRTX","IE00B19Z4B17.USD","BK4139","IE0031619046.USD","IE00B66KJ199.SGD","RA","BK4161","CINV","MEC","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657882619","title":"Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41","url":"https://stock-news.laohu8.com/highlight/detail?id=2657882619","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657882619?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:55","pubTimestamp":1786092941,"startTime":"0","endTime":"0","summary":"In a report released today, Gil Blum from Needham maintained a Buy rating on Artiva Biotherapeutics, Inc., with a price target of $41.00. Gil Blum ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/artiva-therapeutics-buy-rating-reiterated-on-strong-allonk-ra-profile-and-upcoming-phase-iii-price-target-maintained-at-41-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/artiva-therapeutics-buy-rating-reiterated-on-strong-allonk-ra-profile-and-upcoming-phase-iii-price-target-maintained-at-41-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA","LENZ","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661123","title":"Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661123","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661123?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340735/0/en/Artiva-Biotherapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XAR","IE00B66KJ199.SGD","BK4139","IE00B7SZL793.SGD","LU0963586101.USD","BK4187","LU2065731478.USD","BK4006","IE00B19Z4B17.USD","RA","PYZ","IE0031619046.USD","CRS","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657825638","title":"Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657825638","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657825638?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"-- At the EULAR 2026 Congress in June, the Company presented. promising initial single target dose data, which demonstrated the. potential for immune reset in a refractory and heterogeneous SLE. population. CLN-978 also improved lab markers of disease activity. and demonstrated deep, dose-dependent B cell depletion in. peripheral blood as well as dose-dependent recovery with a. -- In Q4 2026, the Company plans to share initial multi-dose regimen. data. The Company also plans to begin Phase 2 expansion in early. 2027 in patients with SLE and in patients with lupus nephritis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","SLE","RA","CGEM","BK4077","BK4199","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108475070","title":"Federal Jury Rules Avilar and RA Capital Guilty of Willfully Misusing Yale University's Trade Secrets","url":"https://stock-news.laohu8.com/highlight/detail?id=1108475070","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108475070?lang=en_us&edition=fundamental","pubTime":"2026-07-27 23:52","pubTimestamp":1785167538,"startTime":"0","endTime":"0","summary":"Biohaven Ltd. and Yale University announced today that a federal jury in the District of Delaware has found Avilar Therapeutics and RA Capital Management liable in a trade secret misappropriation and...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654172210","title":"Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2654172210","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654172210?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:10","pubTimestamp":1785154225,"startTime":"0","endTime":"0","summary":"Biohaven  said Monday that a federal jury has awarded it $1 million in damages over an alleged trade secret misappropriation by Avilar Therapeutics and RA Capital Management.The jury found that after Yale shared confidential technical information about its MODA targeted protein degradation platform with RA Capital related to a possible deal, RA Capital shared the technology with Avilar Therapeutics to develop a rival platform, the company said.Biohaven said it licensed the MODA platform from Yale, which was developed by Yale professor David Spiegel, to develop and commercialize the technology.Yale received $2 million for RA Capital's breach of contract, and $1 million for trade secret misappropriation.\"This verdict confirms what we have said since we filed this case: RA Capital and Avilar improperly used confidential information to advance a competing company, and the jury agreed that they did so willfully and maliciously,\" Biohaven Chief Executive Vlad Coric said in a statement.Avilar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","BK4139","BK4007","BHVN","LENZ","BK4539","LU1093756325.SGD","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652161400","title":"Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652161400","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652161400?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:30","pubTimestamp":1784287800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, July  17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/17/3329034/0/en/Artiva-Biotherapeutics-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","ARTV","RA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}]}}